secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-06-12T20:01:17+00:00
Accession:  0001171843-26-004094
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Corvus stockholders re-elect Miller, Grais; ratify PwC as FY 2026 auditor
-------------------------------------------------------------------------

- Richard A. Miller and Linda S. Grais elected as Class I directors with 58.3M and 53.2M votes for, respectively; 12.0M broker non-votes.
- Ratification of PricewaterhouseCoopers as independent auditor: 72.9M for, 105.7k against, 51.8k abstain.
- Non-binding advisory approval of NEO compensation: 58.9M for, 1.97M against, 64.3k abstain; 12.0M broker non-votes.
- 73.0M shares voted out of 84.1M shares outstanding as of record date April 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/0001171843-26-004094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/f8k_061226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer